GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » 50-Day SMA

Reata Pharmaceuticals (Reata Pharmaceuticals) 50-Day SMA : $159.77 (As of May. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-05-12), Reata Pharmaceuticals's 50-Day SMA is $159.77. It's 20-Day SMA is $171.01 and 200-Day SMA is $N/A.


Competitive Comparison of Reata Pharmaceuticals's 50-Day SMA

For the Biotechnology subindustry, Reata Pharmaceuticals's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reata Pharmaceuticals's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Reata Pharmaceuticals's 50-Day SMA falls into.



Reata Pharmaceuticals  (NAS:RETA) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reata Pharmaceuticals  (NAS:RETA) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Reata Pharmaceuticals 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
5320 Legacy Drive, Plano, TX, USA, 75024
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Executives
Steven Ryder director 234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai director, 10 percent owner C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni officer: EVP, Chief R&D Officer C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand officer: SVP, Chief Accounting Officer 5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni officer: COO, CFO and President C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir officer: Chief Commercial Officer C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger director 85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen officer: SVP, Global Regulatory Affairs C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff director 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr. director C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley officer: See Remarks 5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John officer: See Remarks C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc. other: See footnotes 225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan officer: SVP, Chief Medical Officer 5320 LEGACY DRIVE, PLANO TX 75024

Reata Pharmaceuticals (Reata Pharmaceuticals) Headlines

From GuruFocus